# Data Extraction Form: Study Characteristics

**Study ID**: [Auto-generated]
**Reviewer**: [Name]
**Extraction Date**: [Date]
**Second Reviewer**: [Name]
**Verification Date**: [Date]

## 1. Publication Details

**Title**: ____________________________________________________________

**Authors**: ____________________________________________________________

**Journal**: ____________________________________________________________

**Year of Publication**: ____________________________________________________________

**DOI/PMID**: ____________________________________________________________

**Country**: ____________________________________________________________

**Funding Source**: ____________________________________________________________

## 2. Study Design

**Primary Design**:
- [ ] Randomized Controlled Trial (RCT)
- [ ] Cluster-Randomized Controlled Trial (Cluster-RCT)
- [ ] Interrupted Time Series (ITS)
- [ ] Controlled Before-After (CBA)
- [ ] Other: ____________________________

**Unit of Randomization** (for RCTs/Cluster-RCTs):
- [ ] Individual patient
- [ ] Hospital ward
- [ ] Entire hospital
- [ ] Other: ____________________________

**Number of Study Arms**: ____________________________

**Study Duration**:
- Total duration: ____________________________ months
- Follow-up period: ____________________________ months

## 3. Setting and Participants

**Setting Type**:
- [ ] Academic/teaching hospital
- [ ] Community hospital
- [ ] Tertiary care center
- [ ] Mixed/Other: ____________________________

**Hospital Beds**:
- Total beds: ____________________________
- ICU beds: ____________________________

**Geographic Region**:
- [ ] North America
- [ ] Europe
- [ ] Asia
- [ ] Australia/Oceania
- [ ] South America
- [ ] Africa
- [ ] Multi-continental

**Study Population**:
- [ ] General adult wards only
- [ ] ICU only
- [ ] Mixed ward and ICU
- [ ] Emergency department
- [ ] Other: ____________________________

**Patient Age** (mean/median):
- Adults â‰¥18 years: [ ] Yes [ ] No
- Age range: ____________________________

**Sample Size**:
- Total patients: ____________________________
- Patients per arm: ____________________________

## 4. Baseline AMR Ecology

**Baseline Resistance Rates** (if reported):

**MRSA** (%): ____________________________
**VRE** (%): ____________________________
**ESBL-producing organisms** (%): ____________________________
**CRE** (%): ____________________________
**Pseudomonas resistant** (%): ____________________________
**Other**: ____________________________

**Baseline CDI Rate** (per 10,000 patient-days): ____________________________

**Baseline Antibiotic Consumption**:
- DOT per 1,000 patient-days: ____________________________
- DDD per 1,000 patient-days: ____________________________

## 5. Intervention and Control Details

**Arm 1 (Reference/Control)**:
- Description: ____________________________
- [ ] Usual care/no intervention
- [ ] Other: ____________________________

**Arm 2**:
- Description: ____________________________
- Intervention type(s): ____________________________

**Arm 3**:
- Description: ____________________________
- Intervention type(s): ____________________________

**Arm 4**:
- Description: ____________________________
- Intervention type(s): ____________________________

**Arm 5**:
- Description: ____________________________
- Intervention type(s): ____________________________

## 6. Implementation Details

**Intervention Duration**: ____________________________ months

**Training Provided**: [ ] Yes [ ] No
- If yes, describe: ____________________________

**Resources Required**:
- Personnel: ____________________________
- Technology: ____________________________
- Cost: ____________________________

## 7. Co-interventions

**Infection Control Measures**:
- [ ] Hand hygiene
- [ ] Contact precautions
- [ ] Environmental cleaning
- [ ] Other: ____________________________

**Other ASP Components**:
- [ ] Formulary restriction
- [ ] IV to PO conversion
- [ ] Dose optimization
- [ ] Other: ____________________________

## 8. Outcome Measurement

**Primary Outcomes Measured**:
- [ ] Mortality
- [ ] CDI incidence
- [ ] MDRO incidence
- [ ] Antibiotic consumption (DOT/DDD)
- [ ] Other: ____________________________

**Secondary Outcomes Measured**:
- [ ] Length of stay
- [ ] Antibiotic costs
- [ ] Adverse events
- [ ] Other: ____________________________

## 9. Statistical Analysis

**Primary Analysis Method**:
- [ ] Intention-to-treat
- [ ] Per-protocol
- [ ] Other: ____________________________

**Adjustment Variables**:
- Age: [ ] Yes [ ] No
- Sex: [ ] Yes [ ] No
- Comorbidities: [ ] Yes [ ] No
- Severity of illness: [ ] Yes [ ] No
- Other: ____________________________

## 10. Quality Indicators

**Ethical Approval**: [ ] Yes [ ] No [ ] Not reported

**Informed Consent**: [ ] Yes [ ] No [ ] Not reported [ ] N/A

**Clinical Trial Registration**: ____________________________

**Funding Disclosure**: [ ] Yes [ ] No

## 11. Notes and Comments

**Additional Notes**: ____________________________________________________________

**Uncertainties/Clarifications Needed**: ____________________________________________________________

**Second Reviewer Agreement**: [ ] Yes [ ] No
- If no, describe discrepancies: ____________________________

---

**Data Extraction Quality Check**:
- [ ] All relevant data extracted
- [ ] Outcomes match protocol definitions
- [ ] Effect estimates recorded correctly
- [ ] Second reviewer verification completed
